ChemoCentryx - About the company
ChemoCentryx is an acquired company based in Mountain View (United States), founded in 1997 by Thomas Schall. It operates as a Developing orphan drugs for multiple diseases. ChemoCentryx has raised $80.5M in funding. The company has 421 active competitors, including 140 funded and 116 that have exited. Its top competitors include companies like BeiGene, Biogen and argenx.
Company Details
ChemoCentryx focuses on discovery, development and commercialization of orally-administered small molecule therapeutics for autoimmune diseases, inflammatory disorders and cancer, primarily focused on orphan and rare diseases. Their small molecule product candidates is designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease. Has multiple clinical stage products - orphan and rare disease (Ph 2), chronic kidney disease (Ph 2), immuno-oncology (Ph 2), Crohn's disease (Ph 3), other autoimmune/ inflammatory disease (Ph 2).
- Website
- chemocentryx.com
- Registered Address
- 835 Industrial Rd. Suite 600 San Carlos, CA 94070
Key Metrics
Founded Year
1997
Location
Mountain View, United States
Stage
Acquired
Total Funding
$80.5M in 5 rounds
Latest Funding Round
Ranked
47th among 421 active competitors
Annual Revenue
$10M - $50M as on Dec 31, 2021
Employee Count
44 as on Aug 31, 2026
Exit Details
Acquired by Amgen (Aug 04, 2022)
Legal entities associated with ChemoCentryx
ChemoCentryx is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Chemocentryx, Inc. CIN: 94-3254365 , United States, Active | Nov 07, 1996 | $10M - $50M (As on Dec 31, 2021) | 178 (As on Dec 31, 2021) | - |
ChemoCentryx's acquisition details
ChemoCentryx got acquired by Amgen on Aug 04, 2022.
Click here to take a look at ChemoCentryx's acquisition in detail
Sign up to download ChemoCentryx's company profile
ChemoCentryx's funding and investors
ChemoCentryx has raised a total funding of $80.5M over 5 rounds. Its first funding round was on Jun 17, 2004. Its latest funding round was a Grant (prize money) round on Sep 10, 2019 for $*****. 1 investor participated in its latest round. ChemoCentryx has 12 institutional investors.
Here is the list of recent funding rounds of ChemoCentryx:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Sep 10, 2019 | 7428377 | Grant (prize money) | 3885220 | 7306276 | 8576104 | 6574438 |
Jan 04, 2018 | 2920719 | Post IPO | 4810121 | 1600757 | 9118189 | |
Mar 22, 2007 | 6324659 | Series C | 6210752 | 2087093 | 4407781 |
Access funding benchmarks and valuations. Sign up today!View details of ChemoCentryx's funding rounds and investors
ChemoCentryx's founders and board of directors
Founder? Claim ProfileThe founders of ChemoCentryx is Thomas Schall.
Here are the details of ChemoCentryx's key team members:
- Thomas Schall: Founder & CEO of ChemoCentryx. They are also an angel investor in 1 startup.
View details of ChemoCentryx's Founder profiles and Board Members
ChemoCentryx's employee count trend
ChemoCentryx has 44 employees as of Aug 26. Here is ChemoCentryx's employee count trend over the years:
Uncover ChemoCentryx's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
ChemoCentryx's Competitors and alternates
Top competitors of ChemoCentryx include BeiGene, Biogen and argenx. Here is the list of Top 10 competitors of ChemoCentryx, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
2nd |  Biogen 1978, Cambridge (United States), Public | Developer of therapies for neurodegenerative and immunology disorders | $80M | 78/100 | |
3rd | Developer of antibody-based drugs to treat autoimmune diseases and cancer | $61.9M | 75/100 | ||
4th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
5th |  Abcellera Biologics 2012, Vancouver (Canada), Public | AI-enabled platform for antibodies discovery | $115M | 71/100 | |
6th | Developer of immunotherapeutics for the treatment of cancer and other diseases | $861M | 69/100 | ||
7th | Immunocore 2008, Abingdon (United Kingdom), Public | Developer of bispecific T cell receptor therapies for human diseases | $601M | 69/100 | |
8th | ADMA Biologics 2005, Ramsey (United States), Public | Biopharmaceutical company innovating plasma-derived therapeutics for immune deficiencies and infectious diseases | $17.6M | 68/100 | |
9th |  Nimbus Therapeutics 2009, Cambridge (United States), Series F | Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases | $637M | 68/100 | |
10th | DBV Technologies 2002, Bagneux (France), Public | Developer of products for the treatment of various kinds of food allergies | $68.9M | 68/100 | |
47th | ChemoCentryx 1997, Mountain View (United States), Acquired | Developing orphan drugs for multiple diseases | $80.5M | 58/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on ChemoCentryx's competitors? Click here to see the top ones
ChemoCentryx's Investments and acquisitions
ChemoCentryx has made no investments or acquisitions yet.
Reports related to ChemoCentryx
Here is the latest report on ChemoCentryx's sector:
News related to ChemoCentryx
Filter this listMedia has covered ChemoCentryx for 1 event in last 1 year.
•
•
ChemoCentryx shareholders approve $4.7B merger with AmgenSeeking Alpha•Oct 19, 2022•ChemoCentryx, Amgen
•
•
The M&A Class Action Firm Announces the Investigation of ChemoCentryx, IncICrowdNewswire•Sep 05, 2022•Monteverde, ChemoCentryx
•
•
Weiss Law Reminds, LOTZ, GMTX, AAWW, and CCXI Shareholders About Its Ongoing InvestigationsPR Newswire•Aug 25, 2022•Weisslawllp, CarLotz, Gemini Therapeutics, Atlas Air Worldwide and 1 other
•
Halper Sadeh LLP Is Investigating Whether the Sale of Aerie Pharmaceuticals, Inc. Is Fair to ShareholdersBusiness Wire•Aug 24, 2022•Halper Sadeh, Aerie Pharma, One Medical, ChemoCentryx and 1 other
•
Weiss Law Reminds AAWW, CCXI, HNGR, and U Shareholders About Its Ongoing InvestigationsPR Newswire•Aug 10, 2022•Weisslawllp, ChemoCentryx, Atlas Air Worldwide, Unity and 2 others
•
Halper Sadeh LLP Investigates AAWW, CCXI, IRBTPR Newswire•Aug 10, 2022•Halper Sadeh, Atlas Air Worldwide Holdings, ChemoCentryx, iRobot
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about ChemoCentryx
Explore our recently published companies
- Himsons - Vadodara based, 1988 founded, Unfunded company
- Com2uS Platform Corp - Unfunded company
- Just Print - Unfunded company
